{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:04:03Z","timestamp":1790107443009,"version":"4.0.1"},"reference-count":154,"publisher":"Bentham Science Publishers Ltd.","issue":"28","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21602042"],"award-info":[{"award-number":["21602042"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities of China","doi-asserted-by":"publisher","award":["JZ2019HGTB0062"],"award-info":[{"award-number":["JZ2019HGTB0062"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2020,11,20]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Thiazole is an important 5-membered heterocyclic compound containing nitrogen and sulfur\natoms with various pharmaceutical applications including anti-inflammatory, anti-cancer, anti-viral, hypoglycemic,\nanti-bacterial and anti-fungal activities. Until now, the FDA-approved drugs containing thiazole\nmoiety have achieved great success such as dasatinib and dabrafenib. In recent years, considerable\nresearch has been focused on thiazole derivatives, especially 2,4,5-trisubstituted thiazole derivatives,\ndue to their multiple medicinal applications. This review covers related literature in the past 20 years,\nwhich reported the 2,4,5-trisubstituted thiazole as a privileged scaffold in drug design and activity improvement.\nMoreover, this review aimed to provide greater insights into the rational design of more potent\npharmaceutical molecules based on 2,4,5-trisubstituted thiazole in the future.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026620999200917153856","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T04:16:33Z","timestamp":1600402593000},"page":"2535-2577","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["2,4,5-Trisubstituted Thiazole: A Privileged Scaffold in Drug Design and Activity Improvement"],"prefix":"10.2174","volume":"20","author":[{"given":"Zhen","family":"Zhang","sequence":"first","affiliation":[{"name":"School of Food and Biological Engineering, Key Laboratory of Metabolism and Regulation for Major Diseases of Anhui Higher Education Institutes, Hefei University of Technology, Hefei, Anhui, 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaodong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, 450018, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girdhar Singh","family":"Deora","sequence":"additional","affiliation":[{"name":"Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Shan","family":"Li","sequence":"additional","affiliation":[{"name":"School of Food and Biological Engineering, Key Laboratory of Metabolism and Regulation for Major Diseases of Anhui Higher Education Institutes, Hefei University of Technology, Hefei, Anhui, 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.ejmech.2014.10.058","volume":"97","author":"Rouf A.","year":"2015","unstructured":"Rouf A.; Tanyeli C.; Bioactive thiazole and benzothiazole derivatives. Eur J Med Chem 2015,97,911-927","journal-title":"Eur J Med Chem"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1007\/s00044-011-9685-2","volume":"21","author":"Kashyap S.J.","year":"2011","unstructured":"Kashyap S.J.; Garg V.K.; Sharma P.K.; Kumar N.; Dudhe R.; Gupta J.K.; Thiazoles: having diverse biological activities. Med Chem Res 2011,21(8),2123-2132","journal-title":"Med Chem Res"},{"key":"ref=3","author":"Eicher T.","unstructured":"Eicher T.; Hauptmann S.; Speicher A.;  The chemistry of heterocycles Wiley Online Library: Haboken, 2012","journal-title":"The chemistry of heterocycles"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1002\/chin.200747128","volume":"38","author":"Abele E.","year":"2007","unstructured":"Abele E.; Abele R.; Arsenyan P.; Belyakov S.; Veveris M.; Lukevics E.; Phase-transfer catalytic synthesis and hypocholesterolemic activity of thiazino[3,2-a]benzimidazole and its silicon analogue. ChemInform 2007,38(47)","journal-title":"ChemInform"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/jhet.2827","volume":"54","author":"Mishra R.","year":"2017","unstructured":"Mishra R.; Sharma P.K.; Verma P.K.; Tomer I.; Mathur G.; Dhakad P.K.; Biological potential of thiazole derivatives of synthetic origin. J Heterocycl Chem 2017,54(4),2103-2116","journal-title":"J Heterocycl Chem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1573406415666190614101253","volume":"16","author":"Singh I.P.","year":"2020","unstructured":"Singh I.P.; Gupta S.; Kumar S.; Thiazole compounds as antiviral agents: an update. Med Chem 2020,16(1),4-23","journal-title":"Med Chem"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"Lombardo L.J.","year":"2004","unstructured":"Lombardo L.J.; Lee F.Y.; Chen P.; Norris D.; Barrish J.C.; Behnia K.; Castaneda S.; Cornelius L.A.; Das J.; Doweyko A.M.; Fairchild C.; Hunt J.T.; Inigo I.; Johnston K.; Kamath A.; Kan D.; Klei H.; Marathe P.; Pang S.; Peterson R.; Pitt S.; Schieven G.L.; Schmidt R.J.; Tokarski J.; Wen M.L.; Wityak J.; Borzilleri R.M.; Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004,47(27),6658-6661","journal-title":"J Med Chem"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-54490-3_2","volume":"201","author":"Lindauer M.","year":"2010","unstructured":"Lindauer M.; Hochhaus A.; Dasatinib. Recent Results Cancer Res 2010,201,27-65","journal-title":"Recent Results Cancer Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"Karaman M.W.","year":"2008","unstructured":"Karaman M.W.; Herrgard S.; Treiber D.K.; Gallant P.; Atteridge C.E.; Campbell B.T.; Chan K.W.; Ciceri P.; Davis M.I.; Edeen P.T.; Faraoni R.; Floyd M.; Hunt J.P.; Lockhart D.J.; Milanov Z.V.; Morrison M.J.; Pallares G.; Patel H.K.; Pritchard S.; Wodicka L.M.; Zarrinkar P.P.; A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008,26(1),127-132","journal-title":"Nat Biotechnol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-10-2616","volume":"17","author":"Montero J.C.","year":"2011","unstructured":"Montero J.C.; Seoane S.; Oca\u00f1a A.; Pandiella A.; Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011,17(17),5546-5552","journal-title":"Clin Cancer Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"Shah N.P.","year":"2004","unstructured":"Shah N.P.; Tran C.; Lee F.Y.; Chen P.; Norris D.; Sawyers C.L.; Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004,305(5682),399-401","journal-title":"Science"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1073\/pnas.0409770102","volume":"102","author":"Burgess M.R.","year":"2005","unstructured":"Burgess M.R.; Skaggs B.J.; Shah N.P.; Lee F.Y.; Sawyers C.L.; Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005,102(9),3395-3400","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"Tokarski J.S.","year":"2006","unstructured":"Tokarski J.S.; Newitt J.A.; Chang C.Y.J.; Cheng J.D.; Wittekind M.; Kiefer S.E.; Kish K.; Lee F.Y.; Borzillerri R.; Lombardo L.J.; Xie D.; Zhang Y.; Klei H.E.; The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006,66(11),5790-5797","journal-title":"Cancer Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"Talpaz M.","year":"2006","unstructured":"Talpaz M.; Shah N.P.; Kantarjian H.; Donato N.; Nicoll J.; Paquette R.; Cortes J.; O\u2019Brien S.; Nicaise C.; Bleickardt E.; Blackwood-Chirchir M.A.; Iyer V.; Chen T.T.; Huang F.; Decillis A.P.; Sawyers C.L.; Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006,354(24),2531-2541","journal-title":"N Engl J Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","volume":"109","author":"Hochhaus A.","year":"2007","unstructured":"Hochhaus A.; Kantarjian H.M.; Baccarani M.; Lipton J.H.; Apperley J.F.; Druker B.J.; Facon T.; Goldberg S.L.; Cervantes F.; Niederwieser D.; Silver R.T.; Stone R.M.; Hughes T.P.; Muller M.C.; Ezzeddine R.; Countouriotis A.M.; Shah N.P.; Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007,109(6),2303-2309","journal-title":"Blood"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"Hochhaus A.","year":"2008","unstructured":"Hochhaus A.; Baccarani M.; Deininger M.; Apperley J.F.; Lipton J.H.; Goldberg S.L.; Corm S.; Shah N.P.; Cervantes F.; Silver R.T.; Niederwieser D.; Stone R.M.; Dombret H.; Larson R.A.; Roy L.; Hughes T.; M\u00fcller M.C.; Ezzeddine R.; Countouriotis A.M.; Kantarjian H.M.; Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008,22(6),1200-1206","journal-title":"Leukemia"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"Shah N.P.","year":"2008","unstructured":"Shah N.P.; Kantarjian H.M.; Kim D.W.; R\u00e9a D.; Dorlhiac-Llacer P.E.; Milone J.H.; Vela-Ojeda J.; Silver R.T.; Khoury H.J.; Charbonnier A.; Khoroshko N.; Paquette R.L.; Deininger M.; Collins R.H.; Otero I.; Hughes T.; Bleickardt E.; Strauss L.; Francis S.; Hochhaus A.; Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008,26(19),3204-3212","journal-title":"J Clin Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","volume":"109","author":"Kantarjian H.","year":"2007","unstructured":"Kantarjian H.; Pasquini R.; Hamerschlak N.; Rousselot P.; Holowiecki J.; Jootar S.; Robak T.; Khoroshko N.; Masszi T.; Skotnicki A.; Hellmann A.; Zaritsky A.; Golenkov A.; Radich J.; Hughes T.; Countouriotis A.; Shah N.; Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007,109(12),5143-5150","journal-title":"Blood"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"Hauschild A.","year":"2012","unstructured":"Hauschild A.; Grob J-J.; Demidov L.V.; Jouary T.; Gutzmer R.; Millward M.; Rutkowski P.; Blank C.U.; Miller W.H.; Kaempgen E.; Mart\u00edn-Algarra S.; Karaszewska B.; Mauch C.; Chiarion-Sileni V.; Martin A.M.; Swann S.; Haney P.; Mirakhur B.; Guckert M.E.; Goodman V.; Chapman P.B.; Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012,380(9839),358-365","journal-title":"Lancet"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"B88","DOI":"10.1186\/1476-4598-8-88","volume":"8","author":"Laquerre S.","year":"2009","unstructured":"Laquerre S.; Arnone M.; Moss K.; Yang J.; King A.J.; Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation. Mol Cancer Ther 2009,8(Suppl. 1),B88-B88","journal-title":"Mol Cancer Ther"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2147\/DDDT.S38998","volume":"6","author":"Murali R.","year":"2012","unstructured":"Murali R.; Menzies; Long, G., Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 2012,6,391","journal-title":"Drug Des Devel Ther"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","volume":"379","author":"Falchook G.S.","year":"2012","unstructured":"Falchook G.S.; Long G.V.; Kurzrock R.; Kim K.B.; Arkenau T.H.; Brown M.P.; Hamid O.; Infante J.R.; Millward M.; Pavlick A.C.; O\u2019Day S.J.; Blackman S.C.; Curtis C.M.; Lebowitz P.; Ma B.; Ouellet D.; Kefford R.F.; Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012,379(9829),1893-1901","journal-title":"Lancet"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"8503","DOI":"10.1200\/jco.2010.28.15_suppl.8503","volume":"28","author":"Kefford R.A.","year":"2010","unstructured":"Kefford R.A.; Arkenau H.; Brown M.P.; Phase I\/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010,28(15),8503-8503","journal-title":"J Clin Oncol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"Therasse P.","year":"2000","unstructured":"Therasse P.; Arbuck S.G.; Eisenhauer E.A.; Wanders J.; Kaplan R.S.; Rubinstein L.; Verweij J.; Van Glabbeke M.; van Oosterom A.T.; Christian M.C.; Gwyther S.G.; New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000,92(3),205-216","journal-title":"J Natl Cancer Inst"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","volume":"31","author":"Ascierto P.A.","year":"2013","unstructured":"Ascierto P.A.; Minor D.; Ribas A.; Lebbe C.; O\u2019Hagan A.; Arya N.; Guckert M.; Schadendorf D.; Kefford R.F.; Grob J.J.; Hamid O.; Amaravadi R.; Simeone E.; Wilhelm T.; Kim K.B.; Long G.V.; Martin A.M.; Mazumdar J.; Goodman V.L.; Trefzer U.; Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013,31(26),3205-3211","journal-title":"J Clin Oncol"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"Eisenhauer E. A.","year":"2009","unstructured":"Eisenhauer E. A.; Therasse P.; Bogaerts J.; Schwartz L. H.; Sargent D.; Ford R.; Dancey J.; Arbuck S.; Gwyther S.; Mooney M.; New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer 2009,45(2),0-247","journal-title":"Eur J Cancer"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejmech.2015.12.022","volume":"109","author":"Das D.","year":"2016","unstructured":"Das D.; Sikdar P.; Bairagi M.; Recent developments of 2-aminothiazoles in medicinal chemistry. Eur J Med Chem 2016,109,89-98","journal-title":"Eur J Med Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-11-1971","volume":"18","author":"Wu Y.","year":"2012","unstructured":"Wu Y.; Chen C.; Sun X.; Shi X.; Jin B.; Ding K.; Yeung S-C.J.; Pan J.; Cyclin-dependent kinase 7\/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor \u03b1 and bcr-abl oncogene addiction in malignant hematologic cells. Clin Cancer Res 2012,18(7),1966-1978","journal-title":"Clin Cancer Res"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23030685","volume":"23","author":"Liaras K.","year":"2018","unstructured":"Liaras K.; Fesatidou M.; Geronikaki A.; Thiazoles and thiazolidinones as COX\/LOX inhibitors. Molecules 2018,23(3)","journal-title":"Molecules"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1021\/jm980202u","volume":"42","author":"Jimonet P.","year":"1999","unstructured":"Jimonet P.; Audiau F.; Barreau M.; Blanchard J-C.; Boireau A.; Bour Y.; Col\u00e9no M-A.; Doble A.; Doerflinger G.; Huu C.D.; Donat M.H.; Duchesne J.M.; Ganil P.; Gu\u00e9r\u00e9my C.; Honor E.; Just B.; Kerphirique R.; Gontier S.; Hubert P.; Laduron P.M.; Le Blevec J.; Meunier M.; Miquet J.M.; Nemecek C.; Mignani S.; Riluzole series. Synthesis and in vivo \u201cantiglutamate\u201d activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. J Med Chem 1999,42(15),2828-2843","journal-title":"J Med Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2174\/1573406412666160201121310","volume":"12","author":"Laczkowski K.Z.","year":"2016","unstructured":"Laczkowski K.Z.; Biernasiuk A.; Baranowska-Laczkowska A.; Misiura K.; Malm A.; Plech T.; Paneth A.K.; Biernasiuk A.; Baranowska-Laczkowska A.; Misiura K.; Malm A.; Plech T.; Paneth A.; Synthesis, antibacterial activity, interaction with nucleobase and molecular docking studies of 4-formylbenzoic acid based thiazoles. Med Chem 2016,12(6),553-562","journal-title":"Med Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2014.12.031","volume":"92","author":"Mishra C.B.","year":"2015","unstructured":"Mishra C.B.; Kumari S.; Tiwari M.; Thiazole: a promising heterocycle for the development of potent CNS active agents. Eur J Med Chem 2015,92,1-34","journal-title":"Eur J Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.4155\/fmc-2018-0416","volume":"11","author":"Ayati A.","year":"2019","unstructured":"Ayati A.; Emami S.; Moghimi S.; Foroumadi A.; Thiazole in the targeted anticancer drug discovery. Future Med Chem 2019,11(15),1929-1952","journal-title":"Future Med Chem"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.112016","volume":"188","author":"Sharma P.C.","year":"2020","unstructured":"Sharma P.C.; Bansal K.K.; Sharma A.; Sharma D.; Deep A.; Thiazole-containing compounds as therapeutic targets for cancer therapy. Eur J Med Chem 2020,188","journal-title":"Eur J Med Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejmech.2013.11.017","volume":"72","author":"Tripathi A.C.","year":"2014","unstructured":"Tripathi A.C.; Gupta S.J.; Fatima G.N.; Sonar P.K.; Verma A.; Saraf S.K.; 4-Thiazolidinones: the advances continue\u2026. Eur J Med Chem 2014,72,52-77","journal-title":"Eur J Med Chem"},{"key":"ref=36","first-page":"3526","volume":"5","author":"Vengurlekar S.","year":"2014","unstructured":"Vengurlekar S.; Prachand S.; Jain S.; Gupta R.; Synthesis and Evaluation of some Thiazole derivatives as an Antifungal agent. Int J Pharm Life Sci 2014,5(5),3526-3530","journal-title":"Int J Pharm Life Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1016\/j.ejmech.2010.02.060","volume":"45","author":"Kaur H.","year":"2010","unstructured":"Kaur H.; Kumar S.; Vishwakarma P.; Sharma M.; Saxena K.K.; Kumar A.; Synthesis and antipsychotic and anticonvulsant activity of some new substituted oxa\/thiadiazolylazetidinonyl\/thiazoli-dinonylcarbazoles. Eur J Med Chem 2010,45(7),2777-2783","journal-title":"Eur J Med Chem"},{"key":"ref=38","doi-asserted-by":"crossref","DOI":"10.4274\/tjps.25743","volume":"14","author":"Ulusoy G\u00fczeldemirci N.","year":"2017","unstructured":"Ulusoy G\u00fczeldemirci N.; Karaman B.; Antibacterial, antitubercular and antiviral activity evaluations of some arylidenehydrazide derivatives bearing imidazo [2, 1-b] thiazole moiety Turk J Pharm Sci 2017,14(2)","journal-title":"Turk J Pharm Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1016\/j.bmc.2006.01.033","volume":"14","author":"Dawood K.M.","year":"2006","unstructured":"Dawood K.M.; Abdel-Gawad H.; Rageb E.A.; Ellithey M.; Mohamed H.A.; Synthesis, anticonvulsant, and anti-inflammatory evaluation of some new benzotriazole and benzofuran-based heterocycles. Bioorg Med Chem 2006,14(11),3672-3680","journal-title":"Bioorg Med Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/00397911.2017.1412465","volume":"48","author":"Bondock S.","year":"2018","unstructured":"Bondock S.; Fouda A.M.; Synthesis and evaluation of some new 5-(hetaryl) thiazoles as potential antimicrobial agents. Synth Commun 2018,48(5),561-573","journal-title":"Synth Commun"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1080\/17415993.2018.1441841","volume":"39","author":"Iravani N.","year":"2018","unstructured":"Iravani N.; Keshavarz M.; Allah-Karampour M.; One-pot three-component synthesis of some novel ethyl 3-alkyl-2-thioxo-2, 3-dihydrothiazole-4-carboxylates under solvent-and catalyst-free conditions at room temperature. J Sulfur Chem 2018,39(4),414-421","journal-title":"J Sulfur Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/jhet.3040","volume":"55","author":"Ouf S.A.","year":"2018","unstructured":"Ouf S.A.; Gomha S.M.; Ewies M.M.; Sharawy I.A.; Synthesis, characterization, and anifungal activity evaluation of some novel arylazothiazoles. J Heterocycl Chem 2018,55(1),258-264","journal-title":"J Heterocycl Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1016\/j.bmc.2018.04.056","volume":"26","author":"Ouf S.A.","year":"2018","unstructured":"Ouf S.A.; Gomha S.M.; Eweis M.; Ouf A.S.; Sharawy I.A.; Efficiency of newly prepared thiazole derivatives against some cutaneous fungi. Bioorg Med Chem 2018,26(12),3287-3295","journal-title":"Bioorg Med Chem"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s13738-017-1223-9","volume":"15","author":"Khalil A.","year":"2018","unstructured":"Khalil A.; Elsayed G.A.; Mohamed H.A.; Raafat A.; Utility of chloroacetonitrile in construction of some hitherto novel pyrazole and thiazole derivatives. J Iran Chem Soc 2018,15(1),191-199","journal-title":"J Iran Chem Soc"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1248\/cpb.52.634","volume":"52","author":"Ueda S.","year":"2004","unstructured":"Ueda S.; Terauchi H.; Kawasaki M.; Yano A.; Ido M.; Structure-activity relationships of 2-aminothiazole derivatives as inducible nitric oxide synthase inhibitor. Chem Pharm Bull (Tokyo) 2004,52(5),634-637","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12272-013-0083-9","volume":"36","author":"Tiperciuc B.","year":"2013","unstructured":"Tiperciuc B.; P\u00e2rvu A.; Tamaian R.; Nastas\u0103 C.; Ionu\u0163 I.; Oniga O.; New anti-inflammatory thiazolyl-carbonyl-thiosemicarbazides and thiazolyl-azoles with antioxidant properties as potential iNOS inhibitors. Arch Pharm Res 2013,36(6),702-714","journal-title":"Arch Pharm Res"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.5012\/bkcs.2005.26.11.1771","volume":"26","author":"Zia-ur-Rehman M.","year":"2005","unstructured":"Zia-ur-Rehman M.; Choudary J.A.; Ahmad S.; An efficient synthesis of 2-alkyl-4-hydroxy-2H-1, 2-benzothiazine-3-carboxamide-1, 1-dioxides. Bull Korean Chem Soc 2005,26(11),1771","journal-title":"Bull Korean Chem Soc"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"11066","DOI":"10.1016\/j.tet.2007.08.036","volume":"63","author":"Potewar T.M.","year":"2007","unstructured":"Potewar T.M.; Ingale S.A.; Srinivasan K.V.; Efficient synthesis of 2, 4-disubstituted thiazoles using ionic liquid under ambient conditions: a practical approach towards the synthesis of Fanetizole. Tetrahedron 2007,63(45),11066-11069","journal-title":"Tetrahedron"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.jscs.2012.09.002","volume":"20","author":"Thore S.","year":"2016","unstructured":"Thore S.; Gupta S.V.; Baheti K.G.; Synthesis and pharmacological evaluation of 5-methyl-2-phenylthiazole-4-substituted heteroazoles as a potential anti-inflammatory and analgesic agents. J Saudi Chem Soc 2016,20,S46-S52","journal-title":"J Saudi Chem Soc"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1007\/s00044-014-1222-7","volume":"24","author":"Khillare L.D.","year":"2015","unstructured":"Khillare L.D.; Bhosle M.R.; Deshmukh A.R.; Mane R.A.; Synthesis and anti-inflammatory evaluation of new pyrazoles bearing biodynamic thiazole and thiazolidinone scaffolds. Med Chem Res 2015,24(4),1380-1386","journal-title":"Med Chem Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1021\/jm501127s","volume":"58","author":"Zhu J.","year":"2015","unstructured":"Zhu J.; Han L.; Diao Y.; Ren X.; Xu M.; Xu L.; Li S.; Li Q.; Dong D.; Huang J.; Liu X.; Zhao Z.; Wang R.; Zhu L.; Xu Y.; Qian X.; Li H.; Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase. J Med Chem 2015,58(3),1123-1139","journal-title":"J Med Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1248\/cpb.56.1126","volume":"56","author":"Miwatashi S.","year":"2008","unstructured":"Miwatashi S.; Arikawa Y.; Matsumoto T.; Uga K.; Kanzaki N.; Imai Y.N.; Ohkawa S.; Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as selective adenosine A3 antagonists. Chem Pharm Bull (Tokyo) 2008,56(8),1126-1137","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ejps.2011.05.014","volume":"43","author":"Lagoja I.","year":"2011","unstructured":"Lagoja I.; Pannecouque C.; Griffioen G.; Wera S.; Rojasdelaparra V.M.; Van Aerschot A.; Substituted 2-aminothiazoles are exceptional inhibitors of neuronal degeneration in tau-driven models of Alzheimer\u2019s disease. Eur J Pharm Sci 2011,43(5),386-392","journal-title":"Eur J Pharm Sci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"7555","DOI":"10.1016\/j.bmcl.2012.10.022","volume":"22","author":"Lee Y.S.","year":"2012","unstructured":"Lee Y.S.; Kim H.; Kim Y-H.; Roh E.J.; Han H.; Shin K.J.; Synthesis and structure-activity relationships of tri-substituted thiazoles as RAGE antagonists for the treatment of Alzheimer\u2019s disease. Bioorg Med Chem Lett 2012,22(24),7555-7561","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"5823","DOI":"10.1021\/acs.jmedchem.6b00426","volume":"59","author":"Shidore M.","year":"2016","unstructured":"Shidore M.; Machhi J.; Shingala K.; Murumkar P.; Sharma M.K.; Agrawal N.; Tripathi A.; Parikh Z.; Pillai P.; Yadav M.R.; Benzylpiperidine-linked diarylthiazoles as potential anti-Alzheimer\u2019s agents: synthesis and biological evaluation. J Med Chem 2016,59(12),5823-5846","journal-title":"J Med Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.biopha.2016.05.038","volume":"82","author":"Dos Santos T.A.R.","year":"2016","unstructured":"Dos Santos T.A.R.; da Silva A.C.; Silva E.B.; Gomes P.A.; Esp\u00edndola J.W.P.; Cardoso M.V.; Moreira D.R.M.; Leite A.C.L.; Pereira V.R.; Antitumor and immunomodulatory activities of thiosemicarbazones and 1,3-Thiazoles in Jurkat and HT-29 cells. Biomed Pharmacother 2016,82,555-560","journal-title":"Biomed Pharmacother"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2174\/156802661915190827162456","volume":"19","author":"Duan Y.","year":"2019","unstructured":"Duan Y.; Zhu H.; The Advance in important target proteins. Curr Top Med Chem 2019,19(15),1275-1275","journal-title":"Curr Top Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.2174\/156802661917190828111130","volume":"19","author":"Liu W.","year":"2019","unstructured":"Liu W.; Wang X.; Zhu H.; Duan Y.; Precision tumor medicine and drug targets. Curr Top Med Chem 2019,19(17),1488-1489","journal-title":"Curr Top Med Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.2174\/1568026619666190618130008","volume":"19","author":"Duan Y.","year":"2019","unstructured":"Duan Y.; Liu W.; Tian L.; Mao Y.; Song C.; Targeting tubulin-colchicine site for cancer therapy: inhibitors, antibody- drug conjugates and degradation agents. Curr Top Med Chem 2019,19(15),1289-1304","journal-title":"Curr Top Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"972","DOI":"10.2174\/1568026619666190603094439","volume":"19","author":"Duan Y.T.","year":"2019","unstructured":"Duan Y.T.; Sangani C.B.; Liu W.; Soni K.V.; Yao Y.; New promises to cure cancer and other genetic diseases\/disorders: epi-drugs through epigenetics. Curr Top Med Chem 2019,19(12),972-994","journal-title":"Curr Top Med Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.1021\/jm200392p","volume":"54","author":"Romagnoli R.","year":"2011","unstructured":"Romagnoli R.; Baraldi P.G.; Brancale A.; Ricci A.; Hamel E.; Bortolozzi R.; Basso G.; Viola G.; Convergent synthesis and biological evaluation of 2-amino-4-(3\u2032,4\u2032,5\u2032-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents. J Med Chem 2011,54(14),5144-5153","journal-title":"J Med Chem"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"7083","DOI":"10.1016\/j.bmc.2012.10.001","volume":"20","author":"Romagnoli R.","year":"2012","unstructured":"Romagnoli R.; Baraldi P.G.; Salvador M.K.; Camacho M.E.; Preti D.; Tabrizi M.A.; Bassetto M.; Brancale A.; Hamel E.; Bortolozzi R.; Basso G.; Viola G.; Synthesis and biological evaluation of 2-substituted-4-(3\u2032,4\u2032,5\u2032-trimethoxyphenyl)-5-aryl thiazoles as anticancer agents. Bioorg Med Chem 2012,20(24),7083-7094","journal-title":"Bioorg Med Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1016\/j.bmc.2015.04.055","volume":"23","author":"Wang F.","year":"2015","unstructured":"Wang F.; Yang Z.; Liu Y.; Ma L.; Wu Y.; He L.; Shao M.; Yu K.; Wu W.; Pu Y.; Nie C.; Chen L.; Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity. Bioorg Med Chem 2015,23(13),3337-3350","journal-title":"Bioorg Med Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1016\/j.ejmech.2010.04.038","volume":"45","author":"Giri R.S.","year":"2010","unstructured":"Giri R.S.; Thaker H.M.; Giordano T.; Chen B.; Nuthalapaty S.; Vasu K.K.; Sudarsanam V.; Synthesis and evaluation of quinazolinone derivatives as inhibitors of NF-kappaB, AP-1 mediated transcription and eIF-4E mediated translational activation: inhibitors of multi-pathways involve in cancer. Eur J Med Chem 2010,45(9),3558-3563","journal-title":"Eur J Med Chem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1039\/C6MD00234J","volume":"7","author":"Wu Z.","year":"2016","unstructured":"Wu Z.; Fang Y.; Tang Y.; Xiao M.; Ye J.; Li G.; Hu A.; Synthesis and antitumor evaluation of 5-(benzo [d][1, 3] dioxol-5-ylmethyl)-4-(tert-butyl)-N-arylthiazol-2-amines. MedChemComm 2016,7(9),1768-1774","journal-title":"MedChemComm"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1007\/s11164-017-2915-6","volume":"43","author":"Wu Z.","year":"2017","unstructured":"Wu Z.; Ding N.; Tang Y.; Ye J.; Peng J.; Hu A.; Synthesis and antitumor activity of novel N-(5-benzyl-4-(tert-butyl) thiazol-2-yl)-2-(piperazin-1-yl) acetamides. Res Chem Intermed 2017,43(8),4833-4850","journal-title":"Res Chem Intermed"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3390\/molecules20011357","volume":"20","author":"Gomha S.M.","year":"2015","unstructured":"Gomha S.M.; Ahmed S.A.; Abdelhamid A.O.; Synthesis and cytotoxicity evaluation of some novel thiazoles, thiadiazoles, and pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(1H)-ones incorporating triazole moiety. Molecules 2015,20(1),1357-1376","journal-title":"Molecules"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"21826","DOI":"10.3390\/molecules201219803","volume":"20","author":"Gomha S.M.","year":"2015","unstructured":"Gomha S.M.; Zaki Y.H.; Abdelhamid A.O.; Utility of 3-Acetyl-6-bromo-2H-chromen-2-one for the synthesis of new heterocycles as potential antiproliferative agents. Molecules 2015,20(12),21826-21839","journal-title":"Molecules"},{"key":"ref=69","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21010003","volume":"21","author":"Gomha S.M.","year":"2015","unstructured":"Gomha S.M.; Salaheldin T.A.; Hassaneen H.M.; Abdel-Aziz H.M.; Khedr M.A.; Synthesis, characterization and molecular docking of novel bioactive thiazolyl-thiazole derivatives as promising cytotoxic antitumor drug. Molecules 2015,21(1)","journal-title":"Molecules"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/jhet.3131","volume":"55","author":"Gomha S.M.","year":"2018","unstructured":"Gomha S.M.; Abdelhamid A.O.; Abdelrehem N.A.; Kandeel S.M.; Efficient synthesis of new benzofuran-based thiazoles and investigation of their cytotoxic activity against human breast carcinoma cell lines. J Heterocycl Chem 2018,55(4),995-1001","journal-title":"J Heterocycl Chem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3892\/ijo.21.1.171","volume":"21","author":"Napolitano G.","year":"2002","unstructured":"Napolitano G.; Majello B.; Lania L.; Role of cyclinT\/Cdk9 complex in basal and regulated transcription  (review). Int J Oncol 2002,21(1),171-177","journal-title":"Int J Oncol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ejmech.2013.08.052","volume":"70","author":"Shao H.","year":"2013","unstructured":"Shao H.; Shi S.; Foley D.W.; Lam F.; Abbas A.Y.; Liu X.; Huang S.; Jiang X.; Baharin N.; Fischer P.M.; Wang S.; Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents. Eur J Med Chem 2013,70,447-455","journal-title":"Eur J Med Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.chembiol.2010.07.016","volume":"17","author":"Wang S.","year":"2010","unstructured":"Wang S.; Griffiths G.; Midgley C.A.; Barnett A.L.; Cooper M.; Grabarek J.; Ingram L.; Jackson W.; Kontopidis G.; McClue S.J.; McInnes C.; McLachlan J.; Meades C.; Mezna M.; Stuart I.; Thomas M.P.; Zheleva D.I.; Lane D.P.; Jackson R.C.; Glover D.M.; Blake D.G.; Fischer P.M.; Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol 2010,17(10),1111-1121","journal-title":"Chem Biol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1021\/jm0309957","volume":"47","author":"Wang S.","year":"2004","unstructured":"Wang S.; Meades C.; Wood G.; Osnowski A.; Anderson S.; Yuill R.; Thomas M.; Mezna M.; Jackson W.; Midgley C.; Griffiths G.; Fleming I.; Green S.; McNae I.; Wu S.Y.; McInnes C.; Zheleva D.; Walkinshaw M.D.; Fischer P.M.; 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem 2004,47(7),1662-1675","journal-title":"J Med Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejmech.2014.02.027","volume":"76","author":"Rostom S.A.","year":"2014","unstructured":"Rostom S.A.; Faidallah H.M.; Radwan M.F.; Badr M.H.; Bifunctional ethyl 2-amino-4-methylthiazole-5-carboxylate derivatives: synthesis and in vitro biological evaluation as antimicrobial and anticancer agents. Eur J Med Chem 2014,76,170-181","journal-title":"Eur J Med Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"5080","DOI":"10.1016\/j.ejmech.2010.08.017","volume":"45","author":"Zaharia V.","year":"2010","unstructured":"Zaharia V.; Ignat A.; Palibroda N.; Ngameni B.; Kuete V.; Fokunang C.N.; Moungang M.L.; Ngadjui B.T.; Synthesis of some p-toluenesulfonyl-hydrazinothiazoles and hydrazino-bis-thiazoles and their anticancer activity. Eur J Med Chem 2010,45(11),5080-5085","journal-title":"Eur J Med Chem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1016\/j.bmcl.2016.05.059","volume":"26","author":"He H.","year":"2016","unstructured":"He H.; Wang X.; Shi L.; Yin W.; Yang Z.; He H.; Liang Y.; Synthesis, antitumor activity and mechanism of action of novel 1,3-thiazole derivatives containing hydrazide-hydrazone and carboxamide moiety. Bioorg Med Chem Lett 2016,26(14),3263-3270","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"6555","DOI":"10.1016\/j.bmcl.2010.09.041","volume":"20","author":"Shi H-B.","year":"2010","unstructured":"Shi H-B.; Zhang S-J.; Ge Q-F.; Guo D-W.; Cai C-M.; Hu W-X.; Synthesis and anticancer evaluation of thiazolyl-chalcones. Bioorg Med Chem Lett 2010,20(22),6555-6559","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejmech.2015.10.053","volume":"107","author":"Abou-Seri S.M.","year":"2016","unstructured":"Abou-Seri S.M.; Eldehna W.M.; Ali M.M.; Abou El Ella D.A.; 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation. Eur J Med Chem 2016,107,165-179","journal-title":"Eur J Med Chem"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/app6010008","volume":"6","author":"Cai W-X.","year":"2016","unstructured":"Cai W-X.; Liu A-L.; Li Z-M.; Dong W-L.; Liu X-H.; Sun N-B.; Synthesis and anticancer activity of novel thiazole-5-carboxamide derivatives. Appl Sci (Basel) 2016,6(1),8","journal-title":"Appl Sci (Basel)"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13065-017-0255-7","volume":"11","author":"Gomha S.M.","year":"2017","unstructured":"Gomha S.M.; Kheder N.A.; Abdelaziz M.R.; Mabkhot Y.N.; Alhajoj A.M.; A facile synthesis and anticancer activity of some novel thiazoles carrying 1,3,4-thiadiazole moiety. Chem Cent J 2017,11(1),25","journal-title":"Chem Cent J"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13065-017-0335-8","volume":"11","author":"Gomha S.M.","year":"2017","unstructured":"Gomha S.M.; Abdelaziz M.R.; Kheder N.A.; Abdel-Aziz H.M.; Alterary S.; Mabkhot Y.N.; A facile access and evaluation of some novel thiazole and 1,3,4-thiadiazole derivatives incorporating thiazole moiety as potent anticancer agents. Chem Cent J 2017,11(1),105","journal-title":"Chem Cent J"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4236\/abc.2017.71005","volume":"7","author":"Amin H.K.","year":"2017","unstructured":"Amin H.K.; El-Araby A.M.; Eid S.; Nasr T.; Bondock S.; Leheta O.; Dawoud M.E.; A thiazole analogue exhibits an anti-proliferative effect in different human carcinoma cell lines and its mechanism based on molecular modeling. Adv Biol Chem 2017,7(1),76-87","journal-title":"Adv Biol Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ejmech.2010.11.014","volume":"46","author":"Luo Y.","year":"2011","unstructured":"Luo Y.; Xiao F.; Qian S.; Lu W.; Yang B.; Synthesis and in vitro cytotoxic evaluation of some thiazolylbenzimidazole derivatives. Eur J Med Chem 2011,46(1),417-422","journal-title":"Eur J Med Chem"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"6015","DOI":"10.1016\/j.ejmech.2011.10.013","volume":"46","author":"Romagnoli R.","year":"2011","unstructured":"Romagnoli R.; Baraldi P.G.; Lopez Cara C.; Kimatrai Salvador M.; Bortolozzi R.; Basso G.; Viola G.; Balzarini J.; Brancale A.; Fu X-H.; Li J.; Zhang S.Z.; Hamel E.; One-pot synthesis and biological evaluation of 2-pyrrolidinyl-4-amino-5-(3\u2032,4\u2032,5\u2032-trimethoxybenzoyl)thiazole: a unique, highly active antimicrotubule agent. Eur J Med Chem 2011,46(12),6015-6024","journal-title":"Eur J Med Chem"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1021\/jm9001692","volume":"52","author":"Romagnoli R.","year":"2009","unstructured":"Romagnoli R.; Baraldi P.G.; Carrion M.D.; Cruz-Lopez O.; Cara C.L.; Basso G.; Viola G.; Khedr M.; Balzarini J.; Mahboobi S.; Sellmer A.; Brancale A.; Hamel E.; 2-Arylamino-4-amino-5-aroylthiazoles. \u201cOne-pot\u201d synthesis and biological evaluation of a new class of inhibitors of tubulin polymerization. J Med Chem 2009,52(17),5551-5555","journal-title":"J Med Chem"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0033583508004745","volume":"42","author":"Johnson L.N.","year":"2009","unstructured":"Johnson L.N.; Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 2009,42(1),1-40","journal-title":"Q Rev Biophys"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"pp. 67","DOI":"10.1016\/S0065-230X(08)60352-8","volume":"Vol. 68","author":"Hall M.","year":"1996","unstructured":"Hall M.; Peters G.; Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996,Vol. 68,pp. 67-108","journal-title":"Adv Cancer Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1021\/jm301234k","volume":"56","author":"Schonbrunn E.","year":"2013","unstructured":"Schonbrunn E.; Betzi S.; Alam R.; Martin M.P.; Becker A.; Han H.; Francis R.; Chakrasali R.; Jakkaraj S.; Kazi A.; Sebti S.M.; Cubitt C.L.; Gebhard A.W.; Hazlehurst L.A.; Tash J.S.; Georg G.I.; Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. J Med Chem 2013,56(10),3768-3782","journal-title":"J Med Chem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ejmech.2018.06.015","volume":"155","author":"Ayati A.","year":"2018","unstructured":"Ayati A.; Oghabi Bakhshaiesh T.; Moghimi S.; Esmaeili R.; Majidzadeh-A K.; Safavi M.; Firoozpour L.; Emami S.; Foroumadi A.; Synthesis and biological evaluation of new coumarins bearing 2,4-diaminothiazole-5-carbonyl moiety. Eur J Med Chem 2018,155,483-491","journal-title":"Eur J Med Chem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1021\/jm300388h","volume":"55","author":"Romagnoli R.","year":"2012","unstructured":"Romagnoli R.; Baraldi P.G.; Salvador M.K.; Preti D.; Aghazadeh Tabrizi M.; Brancale A.; Fu X-H.; Li J.; Zhang S-Z.; Hamel E.; Bortolozzi R.; Porc\u00f9 E.; Basso G.; Viola G.; Discovery and optimization of a series of 2-aryl-4-amino-5-(3\u2032,4\u2032,5\u2032-trimethoxybenzoyl)thiazoles as novel anticancer agents. J Med Chem 2012,55(11),5433-5445","journal-title":"J Med Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ejmech.2018.01.015","volume":"145","author":"Ayati A.","year":"2018","unstructured":"Ayati A.; Esmaeili R.; Moghimi S.; Oghabi Bakhshaiesh T.; Eslami-S Z.; Majidzadeh-A K.; Safavi M.; Emami S.; Foroumadi A.; Synthesis and biological evaluation of 4-amino-5-cinnamoylthiazoles as chalcone-like anticancer agents. Eur J Med Chem 2018,145,404-412","journal-title":"Eur J Med Chem"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/380544a0","volume":"380","author":"Lu K.P.","year":"1996","unstructured":"Lu K.P.; Hanes S.D.; Hunter T.; A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 1996,380(6574),544-547","journal-title":"Nature"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1126\/science.287.5458.1644","volume":"287","author":"Winkler K.E.","year":"2000","unstructured":"Winkler K.E.; Swenson K.I.; Kornbluth S.; Means A.R.; Requirement of the prolyl isomerase Pin1 for the replication checkpoint. Science 2000,287(5458),1644-1647","journal-title":"Science"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1358\/dnp.2009.22.7.1414594","volume":"22","author":"Xu G.G.","year":"2009","unstructured":"Xu G.G.; Etzkorn F.A.; Pin1 as an anticancer drug target. Drug News Perspect 2009,22(7),399-407","journal-title":"Drug News Perspect"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1016\/j.bmc.2016.09.049","volume":"24","author":"Zhao H.","year":"2016","unstructured":"Zhao H.; Cui G.; Jin J.; Chen X.; Xu B.; Synthesis and Pin1 inhibitory activity of thiazole derivatives. Bioorg Med Chem 2016,24(22),5911-5920","journal-title":"Bioorg Med Chem"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","volume":"22","author":"Chauhan D.","year":"2012","unstructured":"Chauhan D.; Tian Z.; Nicholson B.; Kumar K.G.; Zhou B.; Carrasco R.; McDermott J.L.; Leach C.A.; Fulcinniti M.; Kodrasov M.P.; Weinstock J.; Kingsbury W.D.; Hideshima T.; Shah P.K.; Minvielle S.; Altun M.; Kessler B.M.; Orlowski R.; Richardson P.; Munshi N.; Anderson K.C.; A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 2012,22(3),345-358","journal-title":"Cancer Cell"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.bmcl.2017.01.018","volume":"27","author":"Chen C.","year":"2017","unstructured":"Chen C.; Song J.; Wang J.; Xu C.; Chen C.; Gu W.; Sun H.; Wen X.; Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors. Bioorg Med Chem Lett 2017,27(4),845-849","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ejmech.2015.04.027","volume":"96","author":"Zhou W.","year":"2015","unstructured":"Zhou W.; Huang A.; Zhang Y.; Lin Q.; Guo W.; You Z.; Yi Z.; Liu M.; Chen Y.; Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents. Eur J Med Chem 2015,96,269-280","journal-title":"Eur J Med Chem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"7648","DOI":"10.1016\/j.bmc.2013.10.030","volume":"21","author":"Salehi M.","year":"2013","unstructured":"Salehi M.; Amini M.; Ostad S.N.; Riazi G.H.; Assadieskandar A.; Shafiei B.; Shafiee A.; Synthesis, cytotoxic evaluation and molecular docking study of 2-alkylthio-4-(2,3,4-trimethoxyphenyl)-5-aryl-thiazoles as tubulin polymerization inhibitors. Bioorg Med Chem 2013,21(24),7648-7654","journal-title":"Bioorg Med Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1101\/gad.183434.111","volume":"26","author":"Hayden M.S.","year":"2012","unstructured":"Hayden M.S.; Ghosh S.; NF-\u03baB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012,26(3),203-234","journal-title":"Genes Dev"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/ar2457","volume":"10","author":"Brown K.D.","year":"2008","unstructured":"Brown K.D.; Claudio E.; Siebenlist U.; The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 2008,10(4),212","journal-title":"Arthritis Res Ther"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1016\/j.bmcl.2017.10.060","volume":"27","author":"Vasu K.K.","year":"2017","unstructured":"Vasu K.K.; Digwal C.S.; Pandya A.N.; Pandya D.H.; Sharma J.A.; Patel S.; Agarwal M.; Imidazo[1,2-a]pyridines linked with thiazoles\/thiophene motif through keto spacer as potential cytotoxic agents and NF-\u03baB inhibitors. Bioorg Med Chem Lett 2017,27(24),5463-5466","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ejmech.2013.01.046","volume":"63","author":"Lefranc F.","year":"2013","unstructured":"Lefranc F.; Xu Z.; Burth P.; Mathieu V.; Revelant G.; de Castro Faria M.V.; Noyon C.; Garcia D.G.; Dufour D.; Bruy\u00e8re C.; Gon\u00e7alves-de-Albuquerque C.F.; Van Antwerpen P.; Rogister B.; Hesse S.; Kirsch G.; Kiss R.; 4-Bromo-2-(piperidin-1-yl)thiazol-5-yl-phenyl methanone (12b) inhibits Na+\/K(+)-ATPase and Ras oncogene activity in cancer cells. Eur J Med Chem 2013,63,213-223","journal-title":"Eur J Med Chem"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejmech.2014.04.013","volume":"80","author":"Reichelt A.","year":"2014","unstructured":"Reichelt A.; Bailis J.M.; Bartberger M.D.; Yao G.; Shu H.; Kaller M.R.; Allen J.G.; Weidner M.F.; Keegan K.S.; Dao J.H.; Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem 2014,80,364-382","journal-title":"Eur J Med Chem"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1021\/jm700956r","volume":"51","author":"Vanotti E.","year":"2008","unstructured":"Vanotti E.; Amici R.; Bargiotti A.; Berthelsen J.; Bosotti R.; Ciavolella A.; Cirla A.; Cristiani C.; D\u2019Alessio R.; Forte B.; Isacchi A.; Martina K.; Menichincheri M.; Molinari A.; Montagnoli A.; Orsini P.; Pillan A.; Roletto F.; Scolaro A.; Tibolla M.; Valsasina B.; Varasi M.; Volpi D.; Santocanale C.; Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships. J Med Chem 2008,51(3),487-501","journal-title":"J Med Chem"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1021\/jm800977q","volume":"52","author":"Menichincheri M.","year":"2009","unstructured":"Menichincheri M.; Bargiotti A.; Berthelsen J.; Bertrand J.A.; Bossi R.; Ciavolella A.; Cirla A.; Cristiani C.; Croci V.; D\u2019Alessio R.; Fasolini M.; Fiorentini F.; Forte B.; Isacchi A.; Martina K.; Molinari A.; Montagnoli A.; Orsini P.; Orzi F.; Pesenti E.; Pezzetta D.; Pillan A.; Poggesi I.; Roletto F.; Scolaro A.; Tat\u00f2 M.; Tibolla M.; Valsasina B.; Varasi M.; Volpi D.; Santocanale C.; Vanotti E.; First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem 2009,52(2),293-307","journal-title":"J Med Chem"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ejmech.2015.01.053","volume":"92","author":"Ram\u00edrez J.","year":"2015","unstructured":"Ram\u00edrez J.; Svetaz L.; Quiroga J.; Abonia R.; Raimondi M.; Zacchino S.; Insuasty B.; Synthesis of novel thiazole-based 8,9-dihydro-7H-pyrimido[4,5-b][1,4]diazepines as potential antitumor and antifungal agents. Eur J Med Chem 2015,92,866-875","journal-title":"Eur J Med Chem"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ejmech.2015.08.020","volume":"102","author":"Jeong K.W.","year":"2015","unstructured":"Jeong K.W.; Lee J.H.; Park S.M.; Choi J-H.; Jeong D-Y.; Choi D-H.; Nam Y.; Park J-H.; Lee K-N.; Kim S-M.; Ku J.M.; Synthesis and in-vitro evaluation of 2-amino-4-arylthiazole as inhibitor of 3D polymerase against foot-and-mouth disease (FMD). Eur J Med Chem 2015,102,387-397","journal-title":"Eur J Med Chem"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejmech.2014.07.072","volume":"85","author":"Xu Z.","year":"2014","unstructured":"Xu Z.; Ba M.; Zhou H.; Cao Y.; Tang C.; Yang Y.; He R.; Liang Y.; Zhang X.; Li Z.; Zhu L.; Guo Y.; Guo C.; 2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase. Eur J Med Chem 2014,85,27-42","journal-title":"Eur J Med Chem"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.bmc.2006.12.003","volume":"15","author":"Rawal R.K.","year":"2007","unstructured":"Rawal R.K.; Tripathi R.; Katti S.B.; Pannecouque C.; De Clercq E.; Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Bioorg Med Chem 2007,15(4),1725-1731","journal-title":"Bioorg Med Chem"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1021\/jm1013538","volume":"54","author":"Mayhoub A.S.","year":"2011","unstructured":"Mayhoub A.S.; Khaliq M.; Kuhn R.J.; Cushman M.; Design, synthesis, and biological evaluation of thiazoles targeting flavivirus envelope proteins. J Med Chem 2011,54(6),1704-1714","journal-title":"J Med Chem"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s12272-012-0604-y","volume":"35","author":"Zhan P.","year":"2012","unstructured":"Zhan P.; Wang L.; Liu H.; Chen X.; Li X.; Jiang X.; Zhang Q.; Liu X.; Pannecouque C.; Naesens L.; De Clercq E.; Liu A.; Du G.; Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents. Arch Pharm Res 2012,35(6),975-986","journal-title":"Arch Pharm Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"4660","DOI":"10.1021\/jm800412d","volume":"51","author":"Li Z.","year":"2008","unstructured":"Li Z.; Khaliq M.; Zhou Z.; Post C.B.; Kuhn R.J.; Cushman M.; Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins. J Med Chem 2008,51(15),4660-4671","journal-title":"J Med Chem"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/pr.108.00802","volume":"60","author":"Stoddart L.A.","year":"2008","unstructured":"Stoddart L.A.; Smith N.J.; Milligan G.; International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev 2008,60(4),405-417","journal-title":"Pharmacol Rev"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1124\/mol.109.055244","volume":"76","author":"Wellendorph P.","year":"2009","unstructured":"Wellendorph P.; Johansen L.D.; Br\u00e4uner-Osborne H.; Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients. Mol Pharmacol 2009,76(3),453-465","journal-title":"Mol Pharmacol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bbrc.2005.07.042","volume":"335","author":"Shapiro H.","year":"2005","unstructured":"Shapiro H.; Shachar S.; Sekler I.; Hershfinkel M.; Walker M.D.; Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochem Biophys Res Commun 2005,335(1),97-104","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bioorg.2018.01.027","volume":"77","year":"2018","unstructured":"Li; Zheng; Xu; Xue; Hou; Jie; Wang; Shaohong; Jiang; Hongwei, Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold. Bioorg Chem 2018,77(9),402-410","journal-title":"Bioorg Chem"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1073\/pnas.0811325106","volume":"106","author":"Artis D.R.","year":"2009","unstructured":"Artis D.R.; Lin J.J.; Zhang C.; Wang W.; Mehra U.; Perreault M.; Erbe D.; Krupka H.I.; England B.P.; Arnold J.; Plotnikov A.N.; Marimuthu A.; Nguyen H.; Will S.; Signaevsky M.; Kral J.; Cantwell J.; Settachatgull C.; Yan D.S.; Fong D.; Oh A.; Shi S.; Womack P.; Powell B.; Habets G.; West B.L.; Zhang K.Y.; Milburn M.V.; Vlasuk G.P.; Hirth K.P.; Nolop K.; Bollag G.; Ibrahim P.N.; Tobin J.F.; Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci USA 2009,106(1),262-267","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=120","doi-asserted-by":"publisher","DOI":"10.1002\/chin.200820258","volume":"39","author":"Rau O.","year":"2008","unstructured":"Rau O.; Zettl H.; Popescu L.; Steinhilber D.; Schubert-Zsilavecz M.; ChemInform Abstract: The treatment of dyslipidemia - what\u2032s left in the pipeline? ChemInform 2008,39(20)","journal-title":"ChemInform"},{"key":"ref=121","doi-asserted-by":"publisher","DOI":"10.1002\/chin.200022291","volume":"31","author":"Willson T.M.","year":"2010","unstructured":"Willson T.M.; Brown P.J.; Sternbach D.D.; Henke B.R.; Cheminform abstract: the ppars: from orphan receptors to drug discovery. ChemInform 2010,31(22)","journal-title":"ChemInform"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.bmc.2010.12.023","volume":"19","author":"Makadia P.","year":"2011","unstructured":"Makadia P.; Shah S.R.; Pingali H.; Zaware P.; Patel D.; Pola S.; Thube B.; Priyadarshini P.; Suthar D.; Shah M.; Giri S.; Trivedi C.; Jain M.; Patel P.; Bahekar R.; Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists. Bioorg Med Chem 2011,19(2),771-782","journal-title":"Bioorg Med Chem"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bmcl.2005.09.060","volume":"16","author":"Pereira R.","year":"2006","unstructured":"Pereira R.; Gaudon C.; Iglesias B.; Germain P.; Gronemeyer H.; de Lera A.R.; Synthesis of the PPARbeta\/\u03b4-selective agonist GW501516 and C4-thiazole-substituted analogs. Bioorg Med Chem Lett 2006,16(1),49-54","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/jhet.1992","volume":"52","author":"Sharma S.","year":"2015","unstructured":"Sharma S.; B\u2019Bhatt, Synthesis, characterization, and biological evaluation of some tri-substituted imidazole\/thiazole derivatives. J Heterocycl Chem 2015,52(4),1126-1131","journal-title":"J Heterocycl Chem"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/00397911.2017.1412465","volume":"48","author":"Bondock S.","year":"2018","unstructured":"Bondock S.; Fouda A.M.; Synthesis and evaluation of some new 5-(hetaryl)thiazoles as potential antimicrobial agents. Synth Commun 2018,48(5),561-573","journal-title":"Synth Commun"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1007\/s00044-011-9661-x","volume":"21","author":"Abdel-Wahab B.F.","year":"2012","unstructured":"Abdel-Wahab B.F.; Abdel-Gawad H.; Awad G.E.A.; Badria F.A.; Synthesis, antimicrobial, antioxidant, anti-inflammatory, and analgesic activities of some new 3-(2\u2032-thienyl)pyrazole-based heterocycles. Med Chem Res 2012,21(7),1418-1426","journal-title":"Med Chem Res"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ejmech.2013.08.054","volume":"69","author":"Makam P.","year":"2013","unstructured":"Makam P.; Kankanala R.; Prakash A.; Kannan T.; 2-(2-Hydrazinyl)thiazole derivatives: design, synthesis and in vitro antimycobacterial studies. Eur J Med Chem 2013,69,564-576","journal-title":"Eur J Med Chem"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ejmech.2012.01.007","volume":"49","author":"Lu X.","year":"2012","unstructured":"Lu X.; Liu X.; Wan B.; Franzblau S.G.; Chen L.; Zhou C.; You Q.; Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2,6-dichlorobenzyloxy)phenyl thiazole, oxazole and imidazole derivatives. Part 2. Eur J Med Chem 2012,49(Part 2),164-171","journal-title":"Eur J Med Chem"},{"key":"ref=129","first-page":"240","volume":"2010","author":"Prajapati A.K.","year":"2010","unstructured":"Prajapati A.K.; Modi V.P.; Synthesis and biological evaluation of amides of aminothiazole derivatives. Asian J Res Chem 2010,2010,240-243","journal-title":"Asian J Res Chem"},{"key":"ref=130","first-page":"948","volume":"42","year":"2007","unstructured":"Samir; Bondock; Wesam; Khalifa; Ahmed; A.; Fadda, Synthesis and antimicrobial evaluation of some new thiazole, thiazolidinone and thiazoline derivatives starting from 1-chloro-3,4-dihydronaphthalene-2-carboxaldehyde. ChemInform 2007,42(7),948-954","journal-title":"ChemInform"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ejmech.2013.09.025","volume":"70","author":"Jeankumar V.U.","year":"2013","unstructured":"Jeankumar V.U.; Renuka J.; Santosh P.; Soni V.; Sridevi J.P.; Suryadevara P.; Yogeeswari P.; Sriram D.; Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors. Eur J Med Chem 2013,70,143-153","journal-title":"Eur J Med Chem"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1021\/jm401905m","volume":"57","author":"Mohammad H.","year":"2014","unstructured":"Mohammad H.; Mayhoub A.S.; Ghafoor A.; Soofi M.; Alajlouni R.A.; Cushman M.; Seleem M.N.; Discovery and characterization of potent thiazoles versus methicillin- and vancomycin-resistant Staphylococcus aureus. J Med Chem 2014,57(4),1609-1615","journal-title":"J Med Chem"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejmech.2013.06.029","volume":"67","author":"Desai N.C.","year":"2013","unstructured":"Desai N.C.; Bhatt N.; Somani H.; Trivedi A.; Synthesis, antimicrobial and cytotoxic activities of some novel thiazole clubbed 1,3,4-oxadiazoles. Eur J Med Chem 2013,67,54-59","journal-title":"Eur J Med Chem"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1002\/slct.201800222","volume":"3","author":"Santosh R.","year":"2018","unstructured":"Santosh R.; Selvam M.K.; Kanekar S.U.; Nagaraja G.K.; Kumar M.; Design, synthesis, dna binding, and docking studies of thiazoles and thiazole-containing triazoles as antibacterials. ChemistrySelect 2018,3(14),3892-3898","journal-title":"ChemistrySelect"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1039\/C4MD00124A","volume":"5","author":"Liaras K.","year":"2014","unstructured":"Liaras K.; Geronikaki A.; Glamolija J.; Sokovi M.; Thiazole-based aminopyrimidines and N-phenylpyrazolines as potent antimicrobial agents: synthesis and biological evaluation. MedChemComm 2014,5(7),915","journal-title":"MedChemComm"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1021\/acs.jafc.8b06935","volume":"67","author":"Guo X.","year":"2019","unstructured":"Guo X.; Zhao B.; Fan Z.; Yang D.; Zhang N.; Wu Q.; Yu B.; Zhou S.; Kalinina T.A.; Belskaya N.P.; Discovery of novel thiazole carboxamides as antifungal succinate dehydrogenase inhibitors. J Agric Food Chem 2019,67(6),1647-1655","journal-title":"J Agric Food Chem"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.3390\/molecules24091741","volume":"24","author":"Althagafi I.","year":"2019","unstructured":"Althagafi I.; El-Metwaly N.; Farghaly T.A.; New series of thiazole derivatives: synthesis, structural elucidation, antimicrobial activity, molecular modeling and moe docking. Molecules 2019,24(9),1741","journal-title":"Molecules"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1146\/annurev.biochem.70.1.535","volume":"70","author":"Vanhaesebroeck B.","year":"2001","unstructured":"Vanhaesebroeck B.; Leevers S.J.; Ahmadi K.; Timms J.; Katso R.; Driscoll P.C.; Woscholski R.; Parker P.J.; Waterfield M.D.; Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001,70(1),535-602","journal-title":"Annu Rev Biochem"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"7578","DOI":"10.1016\/j.bmc.2013.10.042","volume":"21","author":"Oka Y.","year":"2013","unstructured":"Oka Y.; Yabuuchi T.; Oi T.; Kuroda S.; Fujii Y.; Ohtake H.; Inoue T.; Wakahara S.; Kimura K.; Fujita K.; Discovery of N-5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-ylacetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase \u03b3 inhibitor for the treatment of inflammatory diseases. Bioorg Med Chem 2013,21(24),7578-7583","journal-title":"Bioorg Med Chem"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"7534","DOI":"10.1016\/j.bmcl.2012.10.028","volume":"22","author":"Oka Y.","year":"2012","unstructured":"Oka Y.; Yabuuchi T.; Fujii Y.; Ohtake H.; Wakahara S.; Matsumoto K.; Endo M.; Tamura Y.; Sekiguchi Y.; Discovery and optimization of a series of 2-aminothiazole-oxazoles as potent phosphoinositide 3-kinase \u03b3 inhibitors. Bioorg Med Chem Lett 2012,22(24),7534-7538","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1016\/j.bmcl.2012.07.042","volume":"22","author":"Bruce I.","year":"2012","unstructured":"Bruce I.; Akhlaq M.; Bloomfield G.C.; Budd E.; Cox B.; Cuenoud B.; Finan P.; Gedeck P.; Hatto J.; Hayler J.F.; Head D.; Keller T.; Kirman L.; Leblanc C.; Le Grand D.; McCarthy C.; O\u2019Connor D.; Owen C.; Oza M.S.; Pilgrim G.; Press N.E.; Sviridenko L.; Whitehead L.; Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway. Bioorg Med Chem Lett 2012,22(17),5445-5450","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.bmcl.2014.02.004","volume":"24","author":"Certal V.","year":"2014","unstructured":"Certal V.; Halley F.; Virone-Oddos A.; Filoche-Romm\u00e9 B.; Carry J-C.; Gruss-Leleu F.; Bertin L.; Guizani H.; Pilorge F.; Richepin P.; Karlsson A.; Charrier V.; Abecassis P-Y.; Vincent L.; Nicolas J-P.; Lengauer C.; Garcia-Echeverria C.; Schio L.; Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3K\u03b2 inhibitors. Bioorg Med Chem Lett 2014,24(6),1506-1510","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1570161052773951","volume":"3","author":"Agrotis A.","year":"2005","unstructured":"Agrotis A.; Kalinina N.; Bobik A.; Transforming growth factor-\u03b2, cell signaling and cardiovascular disorders. Curr Vasc Pharmacol 2005,3(1),55-61","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1096\/fj.03-1273rev","volume":"18","author":"Leask A.","year":"2004","unstructured":"Leask A.; Abraham D.J.; TGF-\u03b2 signaling and the fibrotic response. FASEB J 2004,18(7),816-827","journal-title":"FASEB J"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.bmcl.2008.01.084","volume":"18","author":"Kim D.K.","year":"2008","unstructured":"Kim D.K.; Choi J.H.; An Y.J.; Lee H.S.; Synthesis and biological evaluation of 5-(pyridin-2-yl)thiazoles as transforming growth factor-beta type1 receptor kinase inhibitors. Bioorg Med Chem Lett 2008,18(6),2122-2127","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.110.003285","volume":"63","author":"Fredholm B.B.","year":"2011","unstructured":"Fredholm B.B.; IJzerman A.P.; Jacobson K.A.; Linden J.; M\u00fcller C.E.; International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev 2011,63(1),1-34","journal-title":"Pharmacol Rev"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrd3955","volume":"12","author":"Chen J-F.","year":"2013","unstructured":"Chen J-F.; Eltzschig H.K.; Fredholm B.B.; Adenosine receptors as drug targets--what are the challenges? Nat Rev Drug Discov 2013,12(4),265-286","journal-title":"Nat Rev Drug Discov"},{"key":"ref=148","first-page":"527","volume":"53","author":"Fredholm B.B.","year":"2001","unstructured":"Fredholm B.B.; IJzerman A.P.; Jacobson K.A.; Klotz K.N.; Linden J.; International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001,53(4),527-552","journal-title":"Pharmacol Rev"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.bmcl.2015.01.040","volume":"25","author":"Pandya D.H.","year":"2015","unstructured":"Pandya D.H.; Sharma J.A.; Jalani H.B.; Pandya A.N.; Sudarsanam V.; Kachler S.; Klotz K.N.; Vasu K.K.; Novel thiazole-thiophene conjugates as adenosine receptor antagonists: synthesis, biological evaluation and docking studies. Bioorg Med Chem Lett 2015,25(6),1306-1309","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1016\/j.bmcl.2010.06.138","volume":"20","author":"Sams A.G.","year":"2010","unstructured":"Sams A.G.; Mikkelsen G.K.e.; Larsen M.; Torup L.; Brennum L.T.; Schr\u00f8der T.J.; Bang-Andersen B.; Hit-to-lead optimization of a series of carboxamides of ethyl 2-amino-4-phenylthiazole-5-carboxylates as novel adenosine A2A receptor antagonists. Bioorg Med Chem Lett 2010,20(17),5241-5244","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.bmc.2010.01.072","volume":"18","author":"Scheiff A.B.","year":"2010","unstructured":"Scheiff A.B.; Yerande S.G.; El-Tayeb A.; Li W.; Inamdar G.S.; Vasu K.K.; Sudarsanam V.; M\u00fcller C.E.; 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem 2010,18(6),2195-2203","journal-title":"Bioorg Med Chem"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.ejmech.2013.03.020","volume":"63","author":"Inamdar G.S.","year":"2013","unstructured":"Inamdar G.S.; Pandya A.N.; Thakar H.M.; Sudarsanam V.; Kachler S.; Sabbadin D.; Moro S.; Klotz K.N.; Vasu K.K.; New insight into adenosine receptors selectivity derived from a novel series of [5-substituted-4-phenyl-1,3-thiazol-2-yl] benzamides and furamides. Eur J Med Chem 2013,63,924-934","journal-title":"Eur J Med Chem"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.bmcl.2008.11.066","volume":"19","author":"Cole A.G.","year":"2009","unstructured":"Cole A.G.; Stauffer T.M.; Rokosz L.L.; Metzger A.; Dillard L.W.; Zeng W.; Henderson I.; Synthesis of 2-amino-5-benzoyl-4-(2-furyl)thiazoles as adenosine A(2A) receptor antagonists. Bioorg Med Chem Lett 2009,19(2),378-381","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cbi.2008.03.011","volume":"173","author":"De S.","year":"2008","unstructured":"De S.; Adhikari S.; Tilak-Jain J.; Menon V.P.; Devasagayam T.P.A.; Antioxidant activity of an aminothiazole compound: possible mechanisms. Chem Biol Interact 2008,173(3),215-223","journal-title":"Chem Biol Interact"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/186026","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/186026\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/186026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T16:39:59Z","timestamp":1627403999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/186026\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":154,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2020,11,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026620999200917153856","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}